ID: h-b9794c8e29
Hypothesis
Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity
TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state. AL002c (Alector) already in Phase II trials, making this the most translation-ready hypothesis.
🧬 Mechanism
🔗 Mechanism from KG for TREM2
Auto-built from this analysis's top knowledge-graph edges.
graph TD
TREM2["TREM2"] -->|regulates| microglial_metabolic_repr["microglial metabolic reprogramming"]
TREM2_deficiency["TREM2 deficiency"] -->|causes| impaired_amyloid_plaque_e["impaired amyloid plaque enclosure"]
TREM2_agonism["TREM2 agonism"] -->|protective against| amyloid_associated_neurot["amyloid-associated neurotoxicity"]
TREM2_agonism_1["TREM2 agonism"] -->|prevents| amyloid_associated_neurot_2["amyloid-associated neurotoxicity"]
TREM2_deficient_microglia["TREM2-deficient microglia"] -.->|inhibits| amyloid_plaque_enclosure["amyloid plaque enclosure"]
TREM2_expression["TREM2 expression"] -->|biomarker for| amyloid_burden["amyloid burden"]
style TREM2 fill:#4fc3f7,stroke:#333,color:#000
style microglial_metabolic_repr fill:#4fc3f7,stroke:#333,color:#000
style TREM2_deficiency fill:#4fc3f7,stroke:#333,color:#000
style impaired_amyloid_plaque_e fill:#4fc3f7,stroke:#333,color:#000
style TREM2_agonism fill:#4fc3f7,stroke:#333,color:#000
style amyloid_associated_neurot fill:#4fc3f7,stroke:#333,color:#000
style TREM2_agonism_1 fill:#4fc3f7,stroke:#333,color:#000
style amyloid_associated_neurot_2 fill:#4fc3f7,stroke:#333,color:#000
style TREM2_deficient_microglia fill:#4fc3f7,stroke:#333,color:#000
style amyloid_plaque_enclosure fill:#4fc3f7,stroke:#333,color:#000
style TREM2_expression fill:#4fc3f7,stroke:#333,color:#000
style amyloid_burden fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Contradicts
R47H is loss-of-function - pharmacologic agonism may not recapitulate endogenous activation
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.2%
Volatility
Low
0.0025
Events (7d)
3
Price History
▼18.0%💾 Resource Usage
API Calls
1
Total Cost
$0.0000
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF AL002c is administered at the Phase II dose (10 mg/kg IV every 4 weeks for 48 weeks) to early-stage Alzheimer's disease subjects with elevated amyloid burden (Centiloid > 50), THEN amyloid-beta pla | Mean reduction in cerebral amyloid-beta PET SUVR of ≥ 0.15 from baseline to week 48 in the AL002c-treated arm versus placebo | — no observation — | pending | 0.35 |
| IF AL002c agonism successfully shifts microglia toward a homeostatic state, THEN CSF concentration of soluble TREM2 (sTREM2) will increase by ≥ 30% and CSF levels of disease-associated microglia marke | ≥ 30% increase in CSF sTREM2 and ≥ 25% decrease in CSF SPP1/opsonin-related DAM markers in the AL002c arm versus placebo at 24 weeks | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (2)
pendingconf 40%
IF AL002c agonism successfully shifts microglia toward a homeostatic state, THEN CSF concentration of soluble TREM2 (sTREM2) will increase by ≥ 30% and CSF levels of disease-associated microglia markers (e.g., TREM2-dependent osteopontin/SPP1) will decrease by ≥ 25% relative to placebo within 24 wee
Predicted outcome: ≥ 30% increase in CSF sTREM2 and ≥ 25% decrease in CSF SPP1/opsonin-related DAM markers in the AL002c arm versus placebo at 24 weeks
Falsification: No significant change or decrease in CSF sTREM2 levels in the treatment arm; DAM marker concentrations remain unchanged or increase, indicating failure to reprogram microglia toward homeostatic state
pendingconf 35%
IF AL002c is administered at the Phase II dose (10 mg/kg IV every 4 weeks for 48 weeks) to early-stage Alzheimer's disease subjects with elevated amyloid burden (Centiloid > 50), THEN amyloid-beta plaque load will decrease by ≥ 15% on [18F]-florbetapir PET standardized uptake value ratio relative to
Predicted outcome: Mean reduction in cerebral amyloid-beta PET SUVR of ≥ 0.15 from baseline to week 48 in the AL002c-treated arm versus placebo
Falsification: No statistically significant reduction in [18F]-florbetapir PET SUVR in the treatment arm relative to placebo at 48 weeks; amyloid burden continues to increase at the same rate as placebo control arm
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.